EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY 4.0

Sintilimab plus cisplatin and nab‐paclitaxel induction treatment for locally advanced borderline‐resectable oesophageal squamous cell carcinoma: A single‐arm, prospective, phase 2 study (NEOCRTEC2001)

Jia-Di Wu, De-Shen Wang iD, Zhi-Qiang Wang, Qiao-Qiao Li, Bin-Yang Xu, Chao Ren, Cai-Yan Fang, Yan Huang, Zhi-Chao Li, Ji-Yang Chen, Qiong Tan, Yu-Hong Li und 1 weitere

Clinical and Translational Medicine · 2026-05 · 16 (5)

DOI: 10.1002/ctm2.70691 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Clinical and Translational Medicine, online erschienen am 11.05.2026. Verfasst von Jia-Di Wu und 12 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guan…. Hauptthemen laut MEDLINE: Paclitaxel, Cisplatin, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province, China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The standard treatment for locally advanced borderline‐resectable esophageal squamous cell carcinoma (BR‐ESCC) is still debated owing to insufficient evidence from clinical trials. An increasing number of clinical studies focus on investigating the use of immunotherapy in the treatment of oesophageal cancer. This phase II trial (NEOCRTEC‐2001) aimed to assess the safety and efficacy of sintilimab in combination with cisplatin and nab‐paclitaxel induction immunochemotherapy followed by surgery for BR‐ESCC.

Methods

The NEOCRTEC2001 trial was a single‐centre, open‐label, nonrandomized, phase II study. Patients diagnosed with BR‐ESCC were enrolled in the study and initially received 2–4 courses of induction immunochemotherapy at first. The subsequent treatment, surgery or definitive chemoradiotherapy, was determined based on reassessment by MDT. The primary endpoint of the study was the R0 resection rate.

Results

From September 2020 to June 2024, a total of 50 eligible patients diagnosed with BR‐ESCC were enrolled. All eligible patients underwent induction immunochemotherapy as the initial treatment. After induction immunochemotherapy, 35 of 50 patients (70.0%) were considered resectable, and 29 patients (58.0%) underwent surgery. R0 resection was achieved in 28 patients (56.0%, 95% CI, 41.4–69.1%), and 9 patients (18.0%) achieved pathological complete response. The median follow‐up time of all patients was 29.43 months. Patients in the R0 resection group demonstrated significantly superior overall survival (OS) and progression‐free survival (PFS) compared to those in the non‐R0 group (OS: not reached vs. 19.84 months; HR .25; 95%CI .08–.79, p = .001; PFS: not reached vs. 19.82 months; HR .30; 95%CI .10–.90, p = .006).

Conclusions

The regimen under investigation did not exhibit the anticipated statistical benefit in enhancing surgical conversion rates for BR‐ESCC. Nevertheless, the treatment strategy of induction immunochemotherapy followed by surgery resulted in significant tumour downstaging and a significant pathological complete response rate. Patients who achieved R0 resection exhibited improved survival outcomes.

Trial registration

The study was registered at ClinicalTrials.gov (NCT04548440) Key points To the best of our knowledge, this is the first trial to evaluate the sintilimab combined with chemotherapy as an induction treatment for patients with BR‐ESCC. The R0 resection rate in this study was 56.0%, and the pCR rate was 18.0%. Patients who achieved R0 resection exhibited improved survival outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PaclitaxelCisplatinEsophageal Squamous Cell CarcinomaEsophageal NeoplasmsAlbuminsAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsHumansProspective StudiesMaleFemaleMiddle AgedAged

Stichwörter der Autor:innen

borderline‐resectable oesophageal squamous cell carcinomaconversion surgeryimmunochemotherapy

Substanzen

PaclitaxelCisplatinAlbuminssintilimabAntibodies, Monoclonal, Humanized130-nm albumin-bound paclitaxel

Autor:innen und Institutionen

  • State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China.
  • The First Clinical Medicine College, Gansu University of Chinese Medicine, Lanzhou, P. R. China.

ORCID-Profile: De-Shen Wang, Hong Yang

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Guangdong Province, China

Zitieren

APA

Wu, J. D., Wang, D. S., Wang, Z. Q., Li, Q. Q., Xu, B. Y., Ren, C., Fang, C. Y., Huang, Y., Li, Z. C., Chen, J. Y., Tan, Q., Li, Y. H., & Yang, H. (2026). Sintilimab plus cisplatin and nab‐paclitaxel induction treatment for locally advanced borderline‐resectable oesophageal squamous cell carcinoma: A single‐arm, prospective, phase 2 study (NEOCRTEC2001). Clinical and Translational Medicine, 16(5). https://doi.org/10.1002/ctm2.70691

Vancouver

Wu JD, Wang DS, Wang ZQ, Li QQ, Xu BY, Ren C, et al. Sintilimab plus cisplatin and nab‐paclitaxel induction treatment for locally advanced borderline‐resectable oesophageal squamous cell carcinoma: A single‐arm, prospective, phase 2 study (NEOCRTEC2001). Clinical and Translational Medicine. 2026;16(5). doi:10.1002/ctm2.70691

BibTeX
@article{Wu2026,
  author = {Wu, Jia-Di and Wang, De-Shen and Wang, Zhi-Qiang and Li, Qiao-Qiao and Xu, Bin-Yang and Ren, Chao and Fang, Cai-Yan and Huang, Yan and Li, Zhi-Chao and Chen, Ji-Yang and Tan, Qiong and Li, Yu-Hong and Yang, Hong},
  title = {Sintilimab plus cisplatin and nab‐paclitaxel induction treatment for locally advanced borderline‐resectable oesophageal squamous cell carcinoma: A single‐arm, prospective, phase 2 study (NEOCRTEC2001)},
  journal = {Clinical and Translational Medicine},
  year = {2026},
  volume = {16},
  number = {5},
  doi = {10.1002/ctm2.70691}
}
Kostenlos starten →